688 related articles for article (PubMed ID: 18596007)
21. Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
Taylor AJ
Am J Cardiol; 2008 Apr; 101(8A):36B-43B. PubMed ID: 18375240
[TBL] [Abstract][Full Text] [Related]
22. Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
Salgado BJ; Salgado JV; Dos Santos AM; Casulari LA
Minerva Cardioangiol; 2010 Oct; 58(5):531-42. PubMed ID: 20948500
[TBL] [Abstract][Full Text] [Related]
23. Is family history a useful tool for detecting children at risk for diabetes and cardiovascular diseases? A public health perspective.
Valdez R; Greenlund KJ; Khoury MJ; Yoon PW
Pediatrics; 2007 Sep; 120 Suppl 2():S78-86. PubMed ID: 17767009
[TBL] [Abstract][Full Text] [Related]
24. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
25. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease.
Levy P
Postgrad Med; 2009 May; 121(3 Suppl 1):7-12. PubMed ID: 19494472
[TBL] [Abstract][Full Text] [Related]
26. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
[TBL] [Abstract][Full Text] [Related]
27. Evaluating obesity and cardiovascular risk factors in children and adolescents.
Spiotta RT; Luma GB
Am Fam Physician; 2008 Nov; 78(9):1052-8. PubMed ID: 19007051
[TBL] [Abstract][Full Text] [Related]
28. Lipids, statins and cardiovascular disease.
Cheifitz R
Climacteric; 2008 Aug; 11(4):347-8; author reply 348-50. PubMed ID: 18645702
[No Abstract] [Full Text] [Related]
29. Antiatherogenic small, dense HDL--guardian angel of the arterial wall?
Kontush A; Chapman MJ
Nat Clin Pract Cardiovasc Med; 2006 Mar; 3(3):144-53. PubMed ID: 16505860
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy in the management of mixed dyslipidaemia.
Cannon CP
J Intern Med; 2008 Apr; 263(4):353-65. PubMed ID: 18324928
[TBL] [Abstract][Full Text] [Related]
31. Primary and secondary disorders of lipid metabolism in pediatrics.
Kwiterovich PO
Pediatr Endocrinol Rev; 2008 Feb; 5 Suppl 2():727-38. PubMed ID: 18317444
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic management of isolated low high-density lipoprotein syndrome.
Bermúdez V; Cano R; Cano C; Bermúdez F; Arraiz N; Acosta L; Finol F; Pabón MR; Amell A; Reyna N; Hidalgo J; Kendall P; Manuel V; Hernández R
Am J Ther; 2008; 15(4):377-88. PubMed ID: 18645343
[TBL] [Abstract][Full Text] [Related]
33. Evaluation critique of state of the art dyslipidemia management in general and with a special emphasis on the Indian population.
Whayne TF
Indian Heart J; 2007; 59(3):218-25. PubMed ID: 19124929
[TBL] [Abstract][Full Text] [Related]
34. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.
Robson J
Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534
[No Abstract] [Full Text] [Related]
35. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
Alagona P
Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
[TBL] [Abstract][Full Text] [Related]
36. Pharmacotherapy of dyslipidemias in the adult population.
Vigna GB; Fellin R
Expert Opin Pharmacother; 2010 Dec; 11(18):3041-52. PubMed ID: 20958118
[TBL] [Abstract][Full Text] [Related]
37. Fenofibrate: treatment of hyperlipidemia and beyond.
Rosenson RS
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1319-30. PubMed ID: 19018684
[TBL] [Abstract][Full Text] [Related]
38. The appropriateness of nicotinic acid derivative use in patients with the metabolic syndrome: insights from the ARBITER 2 study.
Al-Shaer MH; Jerome WP
Am J Cardiol; 2006 Jul; 98(2):275-6. PubMed ID: 16828609
[No Abstract] [Full Text] [Related]
39. [Can cardiovascular events be prevented by raising HDL cholesterol?].
Langslet G; Reikvam A
Tidsskr Nor Laegeforen; 2008 Jun; 128(13):1519-23. PubMed ID: 18587459
[TBL] [Abstract][Full Text] [Related]
40. Screening adolescents for lipid disorders: what is the best approach?
Jenssen BP; Jacobson MS
Adolesc Med State Art Rev; 2008 Dec; 19(3):507-20, x. PubMed ID: 19227389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
